On June 15, Eton Pharmaceuticals Inc Entered Into Amendment To Asset Purchase Deal Dated December 31, 2020 By, Between Co And Azurity; Will Sell Back To Azurity Royalty Interests It Received Under Original Agreement For Total Consideration Of $5.5M
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals has entered into an amendment to its asset purchase deal with Azurity, dated December 31, 2020. Eton will sell back to Azurity the royalty interests it received under the original agreement for a total consideration of $5.5 million.
June 15, 2023 | 8:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eton Pharmaceuticals will sell back royalty interests to Azurity for $5.5 million, amending their asset purchase deal.
Eton Pharmaceuticals is selling back the royalty interests it received under the original agreement with Azurity for $5.5 million. This amendment to the asset purchase deal may not have a significant short-term impact on ETON's stock price, as it is a relatively small transaction. However, it could affect the company's future revenue streams.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100